Effect of beta-blocker dose on mortality after acute coronary syndrome

Authors :: María Blanco Vidal
Francisco Calvo-Iglesias
Cristina García Rodríguez
Isabel Pérez Martínez
Víctor Jimenez-Díaz
Lucía Rioboo-Lestón
Emad Abu-Assi
Rafael Cobas-Paz
Cruz Giraldez Lemos
Andrés Íñiguez-Romo
Sergio Raposeiras-Roubín
José Antonio Baz-Alonso
Emilio Paredes-Galán
Berenice Caneiro-Queija
Beatriz Ogando Guillán
Source :: Revista Portuguesa de Cardiologia, Vol 37, Iss 3, Pp 239-245 (2018), Revista Portuguesa de Cardiologia (English Edition), Vol 37, Iss 3, Pp 239-245 (2018)
Publication Year :: 2018
Publisher :: Elsevier BV, 2018.
Abstract: Introduction: Beta-blocker doses that have been shown to be effective in randomized clinical trials are not commonly used in daily clinical practice. The aim of this study was to analyze whether there is a prognostic benefit of high rather than low doses of beta-blockers after an acute coronary syndrome (ACS). Methods: In this retrospective cohort study, 2092 ACS patients discharged from hospital between June 2013 and January 2016 were classified according to the beta-blocker dose prescribed: high dose (≥50% of the target dose tested in clinical trials) and low dose (

Tools